All In Biotech

Drug Trial Radar · NCT05203692

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Feb 2, 2022

Primary completion

Jan 25, 2023

Study completion Mar 22, 2023

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • DS-7011aDrug

    Intravenous or subcutaneous administration, single dose

  • PlaceboDrug

    Intravenous or subcutaneous administration, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events Following Administration with DS-7011a in Healthy ParticipantsTime frame: Screening (Day -28 to Day -7) up to Day 57 post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Apex Clinical Research (Collaborative Neuroscience Research)

    Long Beach, California

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.